Original Article

Effectiveness and Tolerability of FOLFIRINOX Regime in Metastatic Pancreas Cancer Disease


  • Çağlayan Geredeli
  • Şener Cihan
  • Nurgül Yaşar
  • Abdullah Sakin
  • Orçun Can
  • Mehmet Artaç
  • Mustafa Karaağaç
  • Lokman Koral

Received Date: 11.12.2017 Accepted Date: 08.03.2018 Eur Arc Med Res 2018;34(2):76-81


The use of the FOLFIRINOX regimen in the treatment of metastatic pancreatic cancer prolonged both progression-free survival and overall survival. We wanted to retrospectively investigate the efficacy and safety of firstline FOLFIRINOX regimen use in patients with metastatic pancreatic cancer in the Turkish population.

Material and Methods:

The study was designed as retrospective multicenter. Patients with metastatic pancreatic cancer treated with the first series FOLFIRINOX regimen between the years 2012-2016 were included.


Forty-four patients with metastatic pancreatic cancer were included in the study. 30 patients were male (68.2%) and 14 were female (31.8%). The mean age of the patients was 58.7 (34-73) years. Our median follow-up was 14 months. When the metastatic sites of the patients were examined, 72.7% had liver, 18.2% lung, 18.2% peritoneal, 4.5% lymph nodes and 4.5% bones metastases. There was 40.9% partial response, 13.6% stable disease and 45.4% progression disease in the patients. The median progression- free survival time was 8 months (95% CI 4-12). Median overall survival time was 14 months (95% CI 10.3-17.7), 6 months overall survival was 76.2%, 12 months overall survival was 57.5% and 24 months overall survival was 6%. Grade 3-4 neuropeni was found in 36.4% (grade 3, 27.3%, grade 4 9.1%) and grade 3-4 thrombocytopenia was found in 13.6% of the patients. Grade 3-4 anemia was seen in 14.6% of the patients.Grade 3-4 diarrhea was seen in 4.5% of cases, although grade 1-2 diarrhea was 68% with nonhematologic side effects. Grade 1-2 peripheral sensory neuropathy was observed in 72.7% of the cases, whereas grade 3-4 sensory neuropathy was not detected.


Patients with metastatic pancreatic cancer achieved a overall survival of over 12 months using the FOLFIRINOX regimen. However, grade 3-4 hematologic side-effects were up to 49%.

Keywords: metastatic pancreas cancer, FOLFİRİNOX, Toxicity